Bioxytran BIXT
OTC BIXT
$0.02 +0.00 (+0.00%)
At close: Oct 19, 2026 · 4:00 PM EDT

Bioxytran (BIXT) Accumulated Expenses (2013 - 2026)

Updated

Bioxytran (BIXT) recorded Accumulated Expenses of $843,615 in Q2 2026, up 167.8% from the prior quarter.

Analysis

Bioxytran (BIXT) Accumulated Expenses (2013 - 2026) Analysis & Trends

At the end of FY2025, Bioxytran reported Accumulated Expenses of $577,500.

  • Across earlier years, Accumulated Expenses came in at $223,759 in FY2023.
  • The Q2 2026 figure is the highest quarterly Accumulated Expenses in data going back to Q4 2013.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,164.86 Bn 1,133.45 Bn 19.71 Bn
2 Johnson & Johnson 632.18 Bn 550.71 Bn 17.26 Bn
3 AbbVie 503.53 Bn 476.64 Bn 12.70 Bn
4 Merck 378.03 Bn 332.41 Bn 12.21 Bn
5 Novartis Ag 303.09 Bn 267.08 Bn 11.24 Bn
6 Astrazeneca 266.38 Bn 240.07 Bn 12.86 Bn
7 Amgen 241.24 Bn 196.64 Bn 7.24 Bn
8 Gilead Sciences 193.68 Bn 167.88 Bn 6.22 Bn
9 Pfizer 172.22 Bn 118.87 Bn 10.94 Bn
10 Bioxytran 2.73 Mn 1.57 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 843,615.00
Mar 31, 2026 404,443.00
Dec 31, 2025 577,500.00
Sep 30, 2025 275,140.00
Jun 30, 2025 227,859.00
Mar 31, 2025 182,482.00
Dec 31, 2024 143,642.00
Sep 30, 2024 126,286.00
Dec 31, 2023 223,759.00
Sep 30, 2023 185,967.00
Jun 30, 2023 181,548.00
Mar 31, 2023 149,377.00
Dec 31, 2022 134,581.00
Sep 30, 2022 113,210.00
Jun 30, 2022 122,300.00
Dec 31, 2021 85,685.00
Jun 30, 2018 28,476.00
Mar 31, 2018 26,526.00
Dec 31, 2017 24,576.00
Sep 30, 2017 32,626.00
API Access

Bioxytran Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=BIXT&period=max&api_key=YOUR_API_KEY